Olmesartan Medoxomil, an Angiotensin II Receptor Blocker Ameliorates Insulin Resistance and Decreases Triglyceride Production in Fructose-Fed Rats
|
Accession number;04A0398536
|
| Title;Olmesartan Medoxomil, an Angiotensin II Receptor Blocker Ameliorates Insulin Resistance and Decreases Triglyceride Production in Fructose-Fed Rats |
| Author;
OKADA K
(Showa Univ. School Of Medicine, Tokyo, Jpn)
HIRANO T
(Showa Univ. School Of Medicine, Tokyo, Jpn)
RAN J
(Showa Univ. School Of Medicine, Tokyo, Jpn)
ADACHI M
(Showa Univ. School Of Medicine, Tokyo, Jpn)
|
Journal Title;Hypertens Res
|
Journal Code:Y0303A
|
ISSN:0916-9636
|
|
VOL.27;NO.4;PAGE.293-299(2004)
|
| Figure&Table&Reference;FIG.4, TBL.4, REF.33 |
| Pub. Country;Japan |
| Language;English |
| Abstract;In order to study effects of angiotensin II receptor antagonists on insulin function and triglyceride metabolism impaired in II type diabetes mellitus, using A group of rats fed over five weeks on the bait in which fructose is abundant (insulin resistant animal model) and B group of rats fed on normal bait, 0.01% of olmesartan medoxomil (I) aqueous solution was taken optionally on the last 21 days throughout 5 weeks and insulin function, triglyceride metabolism, blood pressure and the like were compared in vivo. As the result, systolic and diastolic blood pressure was remarkably decreased by I administration in both A and B groups. I improved significantly the insulin sensitivity index in A group without affecting the insulin-independent glucose metabolism, and decreased plasma concentration of triglyceride and nonesterified fatty acid in A group without affecting amount of lipoprotein lipase. Further, I brought the secretion rate of triglyceride back into the normal value. I did not affect insulin sensitivity, triglyceride and plasma parameters in B group. From the above, I seemed to be possible to improve insulin resistance and triglyceride overproducation in insulin resistant animal model, independently of its antihypertensive action. |
|
|
|
Related Articles;
|
|
|
